Kits
Calprotectin (IDK® Calprotectin) (MRP 8/14) (Serum, Plasma) ELISA
Kits
Description
Alternative names of calprotectin:
• MRP8/14, L1, (p8,14), p34, S100 A8/A9
Alternative names of the two proteins forming the heterocomplex calprotectin:
• S100A8, Calgranulin A, MRP8 (Migration inhibition factor-related protein-8),
CP-10 (in mouse)
• S100A9, Calgranulin B, MRP14 (Migration inhibition factor-related protein-14)
Calprotectin is a calcium-binding protein secreted predominantly by neutrophils
and monocytes. The heterocomplex consists of the two proteins, S100A8 (calgranulin
A) and S100A9 (calgranulin B), also designated as MRP8 and MRP14, respectively.
Expression of S100A8 and S100A9 in epithelial tissues was first described in context
with squamous epithelia and with murine and human wound repair. More recently,
an association of S100 protein expression with adenocarcinomas in humans has
emerged. The genes S100A8 and S100A9 are located in a gene cluster on chromosome
1q21, a region in which several rearrangements that occur during tumor development
have been observed.
Elevated MRP8/14 levels have been found in many sites of inflammation and in the
extracellular fluid of patients with many types of inflammatory conditions. The concentration
of MRP8/14 in blood is increased in patients with rheumatoid arthritis,
cystic fibrosis, multiple scerlosis, and HIV infections, while elevated MRP8/14 levels
have been detected in stool of patients with Crohn’s disease and colorectal cancer
[1-5]. Extracellular MRP8/14 has antimicrobial, antigrowth and apoptotic effects. It
suppresses the growth of some fungi and bacteria [1,2]. It also suppresses the proliferation
of several different types of cells including: macrophages, lymphocytes, hematopoietic
progenitors, and tumor cell lines. MRP8/14 can also induce apoptosis of
some tumor cell lines [1,2].
Hermani et al. (2005) [6] reported that enhanced expression of S100A8 and S100A9
is an early event in prostate tumor genesis and may contribute to development and
progression or extension of prostate carcinomas. Furthermore, they tested the value
of S100A9 as a serum marker for prostate cancer comparing the serum concentrations
of S100A9 in cancer patients with healthy controls or patients with benign
prostatic hyperplasia (BPH). Significantly increased S100A9 serum levels in prostate cancer were found in prostate cancer patients compared to patients with BPH, the
latter exhibiting values similar to that obtained for healthy individuals.
• MRP8/14, L1, (p8,14), p34, S100 A8/A9
Alternative names of the two proteins forming the heterocomplex calprotectin:
• S100A8, Calgranulin A, MRP8 (Migration inhibition factor-related protein-8),
CP-10 (in mouse)
• S100A9, Calgranulin B, MRP14 (Migration inhibition factor-related protein-14)
Calprotectin is a calcium-binding protein secreted predominantly by neutrophils
and monocytes. The heterocomplex consists of the two proteins, S100A8 (calgranulin
A) and S100A9 (calgranulin B), also designated as MRP8 and MRP14, respectively.
Expression of S100A8 and S100A9 in epithelial tissues was first described in context
with squamous epithelia and with murine and human wound repair. More recently,
an association of S100 protein expression with adenocarcinomas in humans has
emerged. The genes S100A8 and S100A9 are located in a gene cluster on chromosome
1q21, a region in which several rearrangements that occur during tumor development
have been observed.
Elevated MRP8/14 levels have been found in many sites of inflammation and in the
extracellular fluid of patients with many types of inflammatory conditions. The concentration
of MRP8/14 in blood is increased in patients with rheumatoid arthritis,
cystic fibrosis, multiple scerlosis, and HIV infections, while elevated MRP8/14 levels
have been detected in stool of patients with Crohn’s disease and colorectal cancer
[1-5]. Extracellular MRP8/14 has antimicrobial, antigrowth and apoptotic effects. It
suppresses the growth of some fungi and bacteria [1,2]. It also suppresses the proliferation
of several different types of cells including: macrophages, lymphocytes, hematopoietic
progenitors, and tumor cell lines. MRP8/14 can also induce apoptosis of
some tumor cell lines [1,2].
Hermani et al. (2005) [6] reported that enhanced expression of S100A8 and S100A9
is an early event in prostate tumor genesis and may contribute to development and
progression or extension of prostate carcinomas. Furthermore, they tested the value
of S100A9 as a serum marker for prostate cancer comparing the serum concentrations
of S100A9 in cancer patients with healthy controls or patients with benign
prostatic hyperplasia (BPH). Significantly increased S100A9 serum levels in prostate cancer were found in prostate cancer patients compared to patients with BPH, the
latter exhibiting values similar to that obtained for healthy individuals.